CD137 Antibody Market Size, Share, Growth, and Industry Analysis, By Type (Monoclonal Antibody, Polyclonal Antibody), By Application (Flow Cytometry, ELISA, Immunoprecipitation, Other), Regional Insights and Forecast to 2035

CD137 Antibody Market Overview

The global CD137 Antibody Market size estimated at USD 1693.79 million in 2026 and is projected to reach USD 5418.11 million by 2035, growing at a CAGR of 13.8% from 2026 to 2035.

The CD137 Antibody Market is a specialized segment of the immunology and oncology research industry focused on antibodies targeting CD137, also known as 4-1BB or TNFRSF9, a co-stimulatory receptor expressed on activated T cells. CD137 antibodies are extensively utilized in cancer immunotherapy research, flow cytometry, ELISA, immunoprecipitation, and biomarker discovery. More than 65% of ongoing CD137-related studies are linked to oncology and immune-oncology applications. Over 300 active immunotherapy research programs globally investigate CD137-mediated pathways. The market is supported by increasing adoption of monoclonal antibodies, which account for approximately 78% of CD137 antibody usage in research laboratories and biotechnology facilities. CD137 signaling has demonstrated significant activation of CD8+ T-cell responses, making it a critical target in modern immunological studies.

The United States represents the largest national market for CD137 antibodies due to its advanced biotechnology ecosystem and extensive oncology research infrastructure. The country accounts for more than 42% of global clinical immunotherapy studies involving co-stimulatory immune receptors. Over 1,900 cancer research centers, academic laboratories, and biotechnology organizations actively conduct immune checkpoint research. More than 70% of U.S.-based CD137 antibody demand originates from oncology-focused applications. Federal research institutions allocate billions of dollars annually to cancer immunology programs, supporting demand for research-grade antibodies. Flow cytometry platforms are installed in over 80% of major biomedical research institutions, driving routine utilization of CD137 antibodies for T-cell activation studies and translational research.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 68% demand growth is associated with oncology research, 61% with immunotherapy programs, 57% with T-cell activation studies, and 49% with immune checkpoint investigations.
• Major Market Restraint: Around 44% of laboratories report budget limitations, 38% encounter antibody validation concerns, 29% face reproducibility issues, and 24% experience supply-chain constraints.
• Emerging Trends: Nearly 63% of new research projects involve monoclonal antibodies, 54% focus on immune checkpoint combinations, 46% incorporate multiplex analysis, and 41% utilize advanced flow cytometry applications.
• Regional Leadership: North America accounts for 39% market participation, Europe 28%, Asia-Pacific 25%, and Middle East & Africa 8%.
• Competitive Landscape: The top five suppliers collectively contribute approximately 58% of global product availability, while the leading two companies account for nearly 31% of overall market presence.
• Market Segmentation: Monoclonal antibodies represent 78% of utilization, polyclonal antibodies 22%, while flow cytometry applications contribute 43% of total demand.
• Recent Development: Approximately 52% of new antibody launches support multi-application validation, 47% feature recombinant formats, 39% provide enhanced specificity, and 34% include multiplex compatibility.

CD137 Antibody Market Latest Trends

The CD137 Antibody Market is witnessing rapid expansion due to increasing focus on cancer immunotherapy and immune checkpoint modulation. More than 300 active research initiatives worldwide are investigating CD137-mediated immune activation mechanisms. CD137 antibodies have become essential tools for analyzing activated CD8+ T cells, which are involved in approximately 70% of experimental cancer immunotherapy programs. Monoclonal antibodies dominate research workflows, accounting for approximately 78% of product demand due to their specificity and reproducibility. Advanced flow cytometry applications represent nearly 43% of total CD137 antibody utilization. Research institutions increasingly require antibodies validated for multiple applications, including ELISA, flow cytometry, immunoprecipitation, and immunohistochemistry. Products supporting three or more analytical methods now represent approximately 55% of newly introduced antibody offerings.

Another major trend is the integration of CD137 antibodies into immune profiling panels. More than 46% of immunology laboratories now include CD137 biomarkers within T-cell characterization workflows. Multiparameter flow cytometry platforms with 18-color to 30-color configurations have increased demand for highly validated antibody reagents. Additionally, recombinant antibody technology accounts for approximately 37% of newly developed CD137 antibody products, improving batch consistency and reducing variability. The trend toward precision immunology and personalized oncology continues strengthening demand across academic, pharmaceutical, and biotechnology sectors.

CD137 Antibody Market Dynamics

DRIVER

"Expanding Cancer Immunotherapy Research"

The strongest growth driver for the CD137 Antibody Market is the expansion of cancer immunotherapy research. More than 65% of ongoing CD137-related investigations are linked directly to oncology programs. CD137 functions as a co-stimulatory receptor that enhances activation and proliferation of CD8+ T cells, which are critical for anti-tumor immune responses. Over 300 clinical and preclinical immunotherapy programs globally evaluate immune checkpoint and co-stimulatory pathways. Research involving T-cell activation biomarkers has increased by approximately 52% during the last several years. More than 70% of biotechnology companies developing novel immunotherapies incorporate immune receptor analysis into their development pipelines. Academic institutions continue expanding immune-oncology research capacity, increasing demand for validated CD137 antibodies in translational and preclinical studies.

RESTRAINT

"High Validation and Reproducibility Requirements"

The CD137 Antibody Market faces challenges related to antibody validation and experimental reproducibility. Approximately 38% of researchers identify antibody specificity concerns as a significant purchasing factor. More than 25% of laboratories perform independent validation before incorporating antibodies into critical studies. Batch-to-batch variability affects approximately 19% of research workflows involving biological reagents. Academic laboratories often operate under fixed budgets, with approximately 44% reporting procurement constraints. Validation across multiple applications, including flow cytometry, ELISA, and immunoprecipitation, increases development complexity. In addition, approximately 31% of end users prefer antibodies supported by extensive peer-reviewed data, limiting adoption of newly introduced products.

OPPORTUNITY

"Growth in Immune Checkpoint Combination Research"

Immune checkpoint combination strategies present substantial opportunities for CD137 antibody suppliers. More than 54% of current immunotherapy investigations involve multi-target approaches combining co-stimulatory and inhibitory pathways. CD137 has emerged as a key target due to its ability to enhance T-cell activation and anti-tumor activity. Over 40% of newly initiated oncology research programs evaluate combinations involving immune receptor modulation. Pharmaceutical companies continue increasing investments in biomarker discovery, creating opportunities for research-grade antibodies. Advanced immune profiling platforms are now installed in approximately 62% of major cancer research centers. Growing adoption of multiplex flow cytometry and single-cell analysis technologies further expands application opportunities for CD137 antibodies.

CHALLENGE

"Competitive Saturation Among Antibody Suppliers"

The market contains more than 20 major suppliers offering CD137 antibody products, creating intense competition. Approximately 58% of available products originate from the five largest manufacturers. Product differentiation remains challenging because many antibodies target similar epitopes and applications. Research laboratories increasingly demand comprehensive validation packages, increasing development costs. More than 47% of procurement decisions involve evaluation of publication support and performance consistency. Regulatory requirements related to diagnostic development and translational research applications also create barriers for smaller suppliers. Maintaining quality standards while introducing new recombinant antibody formats remains a critical challenge across the industry.

CD137 Antibody Market Segmentation

Download FREE Sample to learn more about this report.

The CD137 Antibody Market is segmented by antibody type and application. Monoclonal antibodies dominate with approximately 78% market share due to high specificity and reproducibility, while polyclonal antibodies account for 22%. Application analysis indicates flow cytometry as the leading segment with 43% share, followed by ELISA at 26%, immunoprecipitation at 18%, and other research methods at 13%. Increased utilization of immune profiling technologies and oncology biomarker research continues supporting growth across all segments. Advanced immunology laboratories increasingly require antibodies validated for multiple applications, driving demand for premium research-grade products.

BY TYPE

Monoclonal Antibody: Monoclonal antibodies represent approximately 78% of the CD137 Antibody Market. Their dominance is attributed to high specificity, reduced background binding, and consistent performance across experiments. More than 72% of oncology laboratories prefer monoclonal CD137 antibodies for flow cytometry and immune phenotyping. These antibodies are widely used in T-cell activation studies and immunotherapy development programs. Approximately 68% of commercial CD137 antibody products are monoclonal formats. Research institutions conducting immune checkpoint investigations utilize monoclonal antibodies in nearly 75% of experimental protocols. Product validation across ELISA, flow cytometry, and immunoprecipitation further strengthens adoption. Recombinant monoclonal antibody technology accounts for approximately 34% of new monoclonal product introductions.

Polyclonal Antibody: Polyclonal antibodies account for approximately 22% of market demand. These antibodies recognize multiple epitopes and provide enhanced sensitivity in certain analytical applications. Around 31% of exploratory immunology studies continue utilizing polyclonal antibodies because of broader antigen recognition. Polyclonal CD137 antibodies are commonly employed in Western blotting, ELISA, and protein detection workflows. More than 18% of academic laboratories maintain regular procurement of polyclonal reagents for discovery-stage investigations. Production costs remain lower than monoclonal alternatives, supporting adoption among budget-conscious research institutions. Despite slower growth, polyclonal antibodies remain important for antigen screening and early-stage biomarker discovery applications.

BY APPLICATION

Flow Cytometry: Flow cytometry is the leading application segment with approximately 43% market share. More than 80% of major immunology laboratories utilize flow cytometry for T-cell characterization and immune profiling. CD137 serves as a key activation marker in studies involving CD8+ T cells and cancer immunotherapy. Multiparameter cytometry platforms with more than 20 simultaneous markers have significantly increased antibody demand. Approximately 69% of CD137 antibody purchases support flow cytometry-based applications.

ELISA: ELISA accounts for approximately 26% of total demand. CD137 antibodies are widely utilized for protein quantification and biomarker analysis. More than 45% of translational immunology laboratories employ ELISA-based assays for cytokine and receptor investigations. High-throughput screening programs contribute substantially to segment growth. Validation for ELISA applications remains a key purchasing criterion among research institutions.

Immunoprecipitation: Immunoprecipitation contributes approximately 18% of market utilization. This application is important for studying protein interactions and immune signaling pathways. More than 33% of advanced immunology research programs incorporate immunoprecipitation techniques. CD137 antibodies supporting immunoprecipitation are increasingly used in mechanistic oncology studies and receptor interaction analysis.

Other: Other applications account for approximately 13% of the market and include immunohistochemistry, Western blotting, CyTOF analysis, and functional assays. Approximately 29% of biomarker discovery programs employ at least one of these techniques. Growing adoption of spatial biology and single-cell technologies continues creating opportunities within this segment.

CD137 Antibody Market Regional Outlook

Download FREE Sample to learn more about this report.

The CD137 Antibody Market demonstrates strong regional variation driven by biotechnology infrastructure, research funding, and oncology development activities. North America leads with approximately 39% share, followed by Europe at 28%, Asia-Pacific at 25%, and Middle East & Africa at 8%. Cancer immunotherapy research and immune checkpoint investigations remain the primary demand generators across all regions. Academic institutions, pharmaceutical companies, and biotechnology firms collectively account for more than 85% of global procurement activity.

NORTH AMERICA

North America holds approximately 39% of the global CD137 Antibody Market. The region benefits from strong biotechnology investment, advanced research infrastructure, and extensive oncology programs. More than 50% of global immune checkpoint research projects originate from North America. The United States accounts for nearly 88% of regional demand due to the presence of leading pharmaceutical companies and cancer research institutions. Over 1,900 biomedical research organizations routinely conduct immune profiling studies. Flow cytometry adoption exceeds 82% among major academic centers. Approximately 71% of CD137 antibody demand in North America is linked to oncology applications. Government-funded cancer research programs continue supporting antibody procurement and translational studies. Clinical research activity involving co-stimulatory receptors remains among the highest globally, strengthening demand for validated antibody products.

EUROPE

Europe represents approximately 28% of global market share. The region contains more than 700 specialized cancer research institutes and biotechnology organizations. Germany, the United Kingdom, France, Switzerland, and the Netherlands collectively contribute over 65% of regional demand. Academic research accounts for nearly 52% of procurement activity.Flow cytometry applications represent approximately 41% of CD137 antibody usage across Europe. Immunotherapy-related studies continue expanding, with more than 45% of oncology research programs evaluating immune activation biomarkers. Research grants supporting cancer immunology have increased substantially during recent years. The region also demonstrates strong adoption of recombinant antibody technologies, representing approximately 39% of newly purchased products.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 25% of the global CD137 Antibody Market. China, Japan, South Korea, India, and Australia collectively contribute nearly 78% of regional demand. Biotechnology infrastructure development and increased cancer research funding continue driving growth. More than 500 biotechnology startups focused on immunology operate across the region.  Academic institutions represent approximately 57% of procurement activity. Flow cytometry installations have increased significantly, supporting demand for immune profiling reagents. Oncology research contributes nearly 63% of total CD137 antibody consumption. China alone accounts for approximately 42% of Asia-Pacific demand due to expanding biomedical research capabilities and growing immunotherapy development programs.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 8% of global demand. Research activity is concentrated in the Gulf Cooperation Council countries, South Africa, and selected academic centers. More than 60% of regional procurement originates from university research laboratories and government-funded biomedical institutes. Cancer research programs are expanding, with oncology-related applications accounting for approximately 58% of CD137 antibody usage. Flow cytometry remains the dominant analytical method, representing nearly 39% of regional demand. Investments in biotechnology infrastructure and precision medicine initiatives continue supporting gradual market development. Collaborative research projects with European and North American institutions further increase adoption of advanced antibody reagents.

List of Top CD137 Antibody Companies

• Sino Biological, Inc.
• Thermo Fisher
• LifeSpan BioSciences, Inc
• BioLegend
• Abcam
• Bio-Techne
• GeneTex
• Bio-Rad Laboratories, Inc.
• Arigo Biolaboratories Corp.
• Merck
• Cell Signaling Technology, Inc.
• MyBiosource, Inc.
• Boster Biological Technology
• Biocare Medical, LLC
• Signalway Antibody LLC
• NSJ Bioreagents
• Leinco Technologies
• Wuhan Fine Biotech Co., Ltd.
• Elabscience Biotechnology Inc.
• Biotium
• Bioss Inc
• Miltenyi Biotec

List of Top 2 Companies Market Share

• Thermo Fisher: approximately 18% share of the global research antibody distribution segment, supported by more than 100 CD137 antibody variants and extensive life-science distribution networks.
• Bio-Techne: approximately 13% share across research antibody and immunology reagent categories, supported by broad immunology portfolios and strong academic adoption.

Investment Analysis and Opportunities

The CD137 Antibody Market continues attracting investment due to growing demand for cancer immunotherapy research. More than 54% of new immune-oncology programs investigate multi-target immune modulation strategies. Pharmaceutical companies increasingly allocate resources toward biomarker discovery and translational immunology. Approximately 62% of major cancer research centers now operate advanced immune profiling laboratories.

Investment in recombinant antibody technologies has increased significantly, with approximately 37% of newly developed CD137 products utilizing recombinant platforms. Research involving T-cell activation biomarkers accounts for nearly 49% of immunology funding initiatives. Academic institutions continue expanding single-cell sequencing and flow cytometry capabilities, increasing demand for validated antibodies. Emerging opportunities include multiplex immune profiling, companion diagnostic development, and cell therapy research. More than 45% of CAR-T and T-cell engineering programs incorporate immune activation markers such as CD137. Biotechnology firms are increasingly collaborating with academic centers to develop next-generation immunotherapy biomarkers. Demand for highly characterized antibodies suitable for multiple analytical platforms continues creating opportunities for premium product suppliers.

New Product Development

Product innovation within the CD137 Antibody Market focuses on recombinant engineering, enhanced specificity, and multiplex compatibility. Approximately 47% of newly launched antibodies support multiple applications, including flow cytometry, ELISA, and immunoprecipitation. Recombinant antibody formats represent nearly 37% of recent product introductions.

Manufacturers increasingly provide antibodies validated using more than 3 experimental techniques. High-affinity monoclonal antibodies now account for approximately 68% of new launches. Product development also emphasizes reduced lot-to-lot variability, with recombinant technologies improving consistency by nearly 30%.  Advanced fluorophore-conjugated antibodies continue gaining traction. More than 42% of flow cytometry-focused launches include compatibility with multiparameter panels exceeding 18 markers. Novel antibody formats optimized for single-cell analysis and CyTOF applications are expanding market opportunities. Enhanced specificity and lower background staining remain primary innovation priorities across leading manufacturers.

Five Recent Developments

• A comprehensive review published in 2025 documented more than 300 active and completed oncology studies investigating CD137-targeted immunotherapy approaches.
• Multiple manufacturers expanded recombinant CD137 antibody portfolios during 2024, increasing availability of antibodies validated for 3 or more applications.
• New flow cytometry-optimized CD137 antibodies supporting advanced multiparameter immune profiling were introduced in 2024, targeting panels exceeding 20 markers.
• Enhanced monoclonal CD137 antibodies with validated ELISA, immunoprecipitation, and flow cytometry compatibility became commercially available during 2024–2025.
• Research programs investigating CD137-mediated T-cell activation expanded significantly during 2025, supporting broader adoption of CD137 antibody products in oncology laboratories.

Report Coverage of CD137 Antibody Market

The CD137 Antibody Market report provides comprehensive analysis of antibody formats, applications, regional performance, competitive positioning, technological developments, and research adoption trends. The report evaluates monoclonal and polyclonal antibodies across key application areas including flow cytometry, ELISA, immunoprecipitation, and other immunological techniques. Coverage includes more than 20 major suppliers operating across North America, Europe, Asia-Pacific, and Middle East & Africa. The study analyzes demand patterns from academic institutions, biotechnology firms, pharmaceutical companies, and contract research organizations. Approximately 85% of market demand originates from these end-user categories.

The report further examines developments in recombinant antibody engineering, immune profiling technologies, cancer immunotherapy research, and biomarker discovery. Detailed analysis is provided for flow cytometry adoption, which accounts for approximately 43% of application demand. Market assessment also covers oncology research programs, T-cell activation studies, immune checkpoint investigations, and translational medicine initiatives. Competitive benchmarking evaluates product portfolios, application validation capabilities, regional reach, and innovation activities. The report provides strategic insights into opportunities emerging from precision immunology, cell therapy research, multiplex diagnostics, and advanced immune-oncology development programs.